In a case that was billed as profits versus patients, India’s Supreme Court dismissed a petition in which Roche sought to prevent a generic drugmaker from selling a lower-cost version […]
Read MoreFDA declares Novo Nordisk drug manufacturing plant out of compliance
A troubled Indiana contract manufacturing plant recently acquired by Novo Nordisk is considered to not be in compliance with the Food and Drug Administration standards, a serious designation that could […]
Read MoreColorado board makes first-in-nation move, sets payment limit on Amgen drug
In a first-in-the-nation move, a Colorado panel has voted to limit what health plans in the state will pay for a costly arthritis treatment, a step that may encourage other […]
Read MoreNovo Nordisk’s obesity drug Wegovy cleared to treat live disease MASH
Novo Nordisk’s obesity drug Wegovy was cleared by U.S. regulators on Friday to treat an increasingly common liver disease, adding to the list of conditions for which the blockbuster therapy […]
Read MoreWhy a long Covid drug trial failed — and what’s next
This article is published in collaboration with The Sick Times, an online publication covering long Covid. The clinical trial changed Shayna Bhalla’s life. After years with long Covid — debilitated […]
Read MoreAlkermes drug helped narcolepsy patients stay awake in Phase 2 trial
Alkermes’ investigational drug helped people with a type of narcolepsy stay awake during the day in a mid-stage trial, results that boost the company’s potential to compete in what’s predicted […]
Read MoreJ&J suffers a loss over 340B drug discount program
In a setback to Johnson & Johnson, a federal judge ruled that a U.S. government agency did not violate the law when it required the company to seek approval before […]
Read MoreNovo Nordisk’s next-gen obesity drug results a letdown for investors
CHICAGO — Late-stage results of Novo Nordisk’s obesity candidate CagriSema suggest the drug is comparable to Eli Lilly’s Zepbound on safety and efficacy, further data indicating that CagriSema may not […]
Read MoreDosing questions surround Novo Nordisk next-gen weight loss drug
CHICAGO — Novo Nordisk’s next-generation obesity injection targeting the amylin hormone showed substantial weight loss in an early study, but similar efficacy across different doses and high rates of side […]
Read MoreMarea drug cuts type of blood fat in half in study
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech […]
Read More